DK3347014T3 - Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom - Google Patents

Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom Download PDF

Info

Publication number
DK3347014T3
DK3347014T3 DK16767114.8T DK16767114T DK3347014T3 DK 3347014 T3 DK3347014 T3 DK 3347014T3 DK 16767114 T DK16767114 T DK 16767114T DK 3347014 T3 DK3347014 T3 DK 3347014T3
Authority
DK
Denmark
Prior art keywords
diagnosing
syndrome
methods
treating tourette
tourette
Prior art date
Application number
DK16767114.8T
Other languages
English (en)
Inventor
Hakon Hakonarson
Charlly Kao
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Application granted granted Critical
Publication of DK3347014T3 publication Critical patent/DK3347014T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16767114.8T 2015-09-08 2016-09-07 Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom DK3347014T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562215636P 2015-09-08 2015-09-08
US201562215673P 2015-09-08 2015-09-08
US201562215628P 2015-09-08 2015-09-08
US201562215633P 2015-09-08 2015-09-08
PCT/US2016/050573 WO2017044497A1 (en) 2015-09-08 2016-09-07 Methods of diagnosing and treating tourette syndrome

Publications (1)

Publication Number Publication Date
DK3347014T3 true DK3347014T3 (da) 2021-12-06

Family

ID=56943962

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16767115.5T DK3347015T3 (da) 2015-09-08 2016-09-07 Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser
DK16767112.2T DK3347013T3 (da) 2015-09-08 2016-09-07 Ikke-selektive metabotropiske glutamatreceptoraktivatorer til behandling af opmærksomhedsforstyrrelse og 22q-syndrom
DK16771034.2T DK3347016T3 (da) 2015-09-08 2016-09-07 Diagnosticering og behandling af angstlidelse
DK16767114.8T DK3347014T3 (da) 2015-09-08 2016-09-07 Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK16767115.5T DK3347015T3 (da) 2015-09-08 2016-09-07 Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser
DK16767112.2T DK3347013T3 (da) 2015-09-08 2016-09-07 Ikke-selektive metabotropiske glutamatreceptoraktivatorer til behandling af opmærksomhedsforstyrrelse og 22q-syndrom
DK16771034.2T DK3347016T3 (da) 2015-09-08 2016-09-07 Diagnosticering og behandling af angstlidelse

Country Status (12)

Country Link
US (12) US11173153B2 (da)
EP (9) EP3977996B1 (da)
JP (8) JP7152306B2 (da)
CN (7) CN116919962A (da)
AU (8) AU2016318780B2 (da)
CA (5) CA2997188A1 (da)
DK (4) DK3347015T3 (da)
ES (4) ES2876898T3 (da)
HK (4) HK1258448A1 (da)
IL (10) IL290993B2 (da)
SG (1) SG10202012842SA (da)
WO (4) WO2017044503A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6216486B2 (ja) 2010-08-24 2017-10-18 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法
IL290993B2 (en) 2015-09-08 2023-11-01 Childrens Hospital Philadelphia Methods for diagnosis and treatment of Tourette syndrome
WO2017210502A1 (en) * 2016-06-03 2017-12-07 Yale University Methods and apparatus for predicting depression treatment outcomes
WO2018048868A1 (en) * 2016-09-07 2018-03-15 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
WO2018195184A1 (en) 2017-04-19 2018-10-25 Aevi Genomics Medicine, Inc. Methods of diagnosing and treating adhd in biomarker positive subjects
US20200061155A1 (en) * 2017-05-11 2020-02-27 Ophidion, Inc Compositions and methods for treating lynx2 disorders
CN107483425B (zh) * 2017-08-08 2020-12-18 北京盛华安信息技术有限公司 基于攻击链的复合攻击检测方法
TW201932453A (zh) * 2018-01-18 2019-08-16 美商艾維基因醫學股份有限公司 法索西坦(fasoracetam)之固體型態
KR20200135771A (ko) * 2018-01-18 2020-12-03 더 칠드런스 호스피탈 오브 필라델피아 파소라세탐 결정질 형태
KR102250063B1 (ko) * 2019-06-14 2021-05-12 한국생명공학연구원 뚜렛증후군의 원인 유전자를 동정하는 방법
CN110955751A (zh) * 2019-11-13 2020-04-03 广州供电局有限公司 工作票文本去重方法、装置、系统及计算机存储介质
MX2023003258A (es) * 2020-09-21 2023-05-08 Reveragen Biopharma Inc Tratamiento de enfermedades mediadas por nf-kb.
WO2022065518A1 (ja) * 2020-09-23 2022-03-31 国立大学法人京都大学 神経突起伸長促進剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523557A (ja) 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
US20050233321A1 (en) 2001-12-20 2005-10-20 Hess John W Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
US20070244152A1 (en) 2004-03-25 2007-10-18 Lowy Martin T Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200819458A (en) 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
WO2008118258A2 (en) 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
US9012143B2 (en) 2007-04-30 2015-04-21 The Ohio State University Research Foundation Polymorphisms in genes affecting ace-related disorders and uses thereof
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
WO2009105718A1 (en) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
WO2010057112A2 (en) 2008-11-14 2010-05-20 The Children's Hospital Of Philadelphia Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2010057132A1 (en) 2008-11-14 2010-05-20 The Children's Hospital Of Philadelphia Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same
WO2011022312A1 (en) * 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
US8714471B2 (en) * 2010-07-29 2014-05-06 Brady Worldwide, Inc. Friction core brake
JP6216486B2 (ja) * 2010-08-24 2017-10-18 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法
US20130225623A1 (en) 2010-10-27 2013-08-29 Mount Sinai School Of Medicine Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2015002378A (es) * 2012-08-23 2015-09-25 Stuart L Weg Composicion ansiolitica, formulacion y metodo de uso.
US9346239B2 (en) 2012-09-26 2016-05-24 Eastman Kodak Company Method for providing patterns of functional materials
WO2014152965A2 (en) 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
AU2015298618A1 (en) 2014-05-30 2016-12-08 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism
US11219617B2 (en) 2014-05-30 2022-01-11 The Children's Hospital Of Philadelphia Methods of diagnosing and treating autism
KR102232583B1 (ko) 2015-01-08 2021-03-26 삼성전자주식회사 전자장치 및 전자장치의 웹 재현 방법
WO2016205348A1 (en) 2015-06-15 2016-12-22 The Children's Hospital Of Philadelphia Methods of diagnosing and treating autism
IL290993B2 (en) 2015-09-08 2023-11-01 Childrens Hospital Philadelphia Methods for diagnosis and treatment of Tourette syndrome

Also Published As

Publication number Publication date
HK1258373A1 (zh) 2019-11-08
CN108348517B (zh) 2021-11-05
IL290993B2 (en) 2023-11-01
EP3977996B1 (en) 2024-03-13
IL300474A (en) 2023-04-01
US20180110767A1 (en) 2018-04-26
JP7027308B2 (ja) 2022-03-01
IL290993B1 (en) 2023-07-01
US20210205288A1 (en) 2021-07-08
JP2023036671A (ja) 2023-03-14
HK1258447A1 (zh) 2019-11-15
WO2017044502A1 (en) 2017-03-16
EP3347014A1 (en) 2018-07-18
CA2997189A1 (en) 2017-03-16
JP7152306B2 (ja) 2022-10-12
ES2876898T3 (es) 2021-11-15
CN108348518A (zh) 2018-07-31
US20220296582A1 (en) 2022-09-22
DK3347015T3 (da) 2021-12-06
EP3347015B1 (en) 2021-10-20
US11179378B2 (en) 2021-11-23
ES2897953T3 (es) 2022-03-03
CA2997187A1 (en) 2017-03-16
IL257746B (en) 2022-04-01
IL290992B1 (en) 2023-03-01
IL257744A (en) 2018-06-28
AU2016318775B2 (en) 2022-02-10
AU2016318780B2 (en) 2022-04-07
EP3347015A1 (en) 2018-07-18
US20170087140A1 (en) 2017-03-30
JP2018526395A (ja) 2018-09-13
JP2023011558A (ja) 2023-01-24
IL257785B (en) 2022-04-01
EP4023222A1 (en) 2022-07-06
JP2018526394A (ja) 2018-09-13
EP3964213A1 (en) 2022-03-09
CA2997191A1 (en) 2017-03-16
DK3347016T3 (da) 2021-07-12
US20220117954A1 (en) 2022-04-21
EP3977996A1 (en) 2022-04-06
US20170087141A1 (en) 2017-03-30
CA2997188A1 (en) 2017-03-16
JP2018526398A (ja) 2018-09-13
JP2018526396A (ja) 2018-09-13
CN116919961A (zh) 2023-10-24
IL257747B (en) 2022-04-01
DK3347013T3 (da) 2022-04-04
EP3347013B1 (en) 2022-02-16
EP3347016B1 (en) 2021-04-28
JP7281279B2 (ja) 2023-05-25
CN108348517A (zh) 2018-07-31
AU2022204324A1 (en) 2022-07-07
IL257785A (en) 2018-06-28
IL290985A (en) 2022-05-01
CN115919852A (zh) 2023-04-07
IL257744B (en) 2022-04-01
IL290993A (en) 2022-05-01
EP3347014B1 (en) 2021-10-20
US20200306237A1 (en) 2020-10-01
CN116919962A (zh) 2023-10-24
AU2022204355A1 (en) 2022-07-14
AU2016318785B2 (en) 2022-04-14
AU2016318786A1 (en) 2018-04-12
CA3225374A1 (en) 2017-03-16
US20240075022A1 (en) 2024-03-07
AU2016318785A1 (en) 2018-04-12
JP2022078104A (ja) 2022-05-24
JP7281280B2 (ja) 2023-05-25
IL290994A (en) 2022-05-01
US11298347B2 (en) 2022-04-12
CN108601776A (zh) 2018-09-28
IL257746A (en) 2018-06-28
EP4342493A2 (en) 2024-03-27
EP3347016A1 (en) 2018-07-18
EP3347013A1 (en) 2018-07-18
WO2017044497A1 (en) 2017-03-16
EP3922249B1 (en) 2024-02-28
IL290992A (en) 2022-05-01
CN108495630A (zh) 2018-09-04
CA2997187C (en) 2024-02-20
US11806340B2 (en) 2023-11-07
AU2016318786B2 (en) 2022-04-07
EP3922249A1 (en) 2021-12-15
IL303605A (en) 2023-08-01
EP3964213B1 (en) 2024-03-13
AU2022203039A1 (en) 2022-05-26
HK1258448A1 (zh) 2019-11-15
WO2017044503A1 (en) 2017-03-16
WO2017044491A1 (en) 2017-03-16
SG10202012842SA (en) 2021-01-28
JP2023051937A (ja) 2023-04-11
US9884057B2 (en) 2018-02-06
AU2022205142A1 (en) 2022-07-28
US11806341B2 (en) 2023-11-07
ES2909329T3 (es) 2022-05-06
US20220117953A1 (en) 2022-04-21
AU2016318775A1 (en) 2018-04-12
US20170087139A1 (en) 2017-03-30
US20240100036A1 (en) 2024-03-28
IL257747A (en) 2018-06-28
IL290992B2 (en) 2023-07-01
AU2016318780A1 (en) 2018-04-12
ES2898932T3 (es) 2022-03-09
HK1258446A1 (zh) 2019-11-15
US10869861B2 (en) 2020-12-22
US11173153B2 (en) 2021-11-16
US20170105985A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
DK3347014T3 (da) Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom
DK3842442T3 (da) Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet
DK3368541T3 (da) Sammensætninger og metoder til inhibiering af arginaseaktivitet
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
BR112016026939A2 (pt) aparelho e método.
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3146035T3 (da) Biofilmmedier, behandlingssystem og behandlingsfremgangsmåde
DK3139903T3 (da) Vandig oftalmisk opløsning og fremgangsmåde til behandling af tørre øjne-syndrom
DK3283136T3 (da) Hydrofile belægninger og fremgangsmåder til dannelse heraf
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3346056T3 (da) Rengøringssystem og fremgangsmåde
DK2963076T3 (da) Hydrofile blok-copolymerer og membraner fremstillet deraf
DK3094640T3 (da) Fremgangsmåder til steril kromatografi og fremstilling
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme